Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review

被引：44

作者：

Fajgenbaum, David C. ^{[1
]}

Khor, Johnson S. ^{[1
]}

Gorzewski, Alexander ^{[1
]}

Tamakloe, Mark-Avery ^{[1
]}

Powers, Victoria ^{[1
]}

Kakkis, Joseph J. ^{[3
]}

Repasky, Mileva ^{[5
]}

Taylor, Anne ^{[6
]}

Beschloss, Alexander ^{[2
]}

Hernandez-Miyares, Laura ^{[2
]}

Go, Beatrice ^{[2
]}

Nimgaonkar, Vivek ^{[2
]}

McCarthy, Madison S. ^{[4
]}

Kim, Casey J. ^{[2
]}

Pai, Ruth-Anne Langan ^{[1
]}

Frankl, Sarah ^{[2
]}

Angelides, Philip ^{[2
]}

Jiang, Joanna ^{[2
]}

Rasheed, Rozena ^{[1
]}

Napier, Erin ^{[7
]}

Mackay, Duncan ^{[8
]}

Pierson, Sheila K. ^{[1
]}

机构：

[1] Univ Penn, Dept MedR, Div Translat Med & Human Genet, Perelman Sch Med, Philadelphia, PA 19104 USA

[2] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

[3] Univ Penn, Philadelphia, PA 19104 USA

[4] Brown Univ, Providence, RI 02912 USA

[5] Castleman Dis Collaborat Network, Philadelphia, PA USA

[6] Ohio State Univ, Coll Med, Columbus, OH 43210 USA

[7] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA

[8] Univ Penn, Dept Surg, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

INFECTIOUS DISEASES AND THERAPY | 2020年 / 9卷 / 03期

关键词：

COVID-19; Drug repurposing; SARS-CoV-2; Systematic literature review; ACUTE RESPIRATORY SYNDROME; SYNDROME CORONAVIRUS; CONVALESCENT PLASMA; SARS CORONAVIRUS; REPLICATION; LOPINAVIR/RITONAVIR; SUSCEPTIBILITY; MODULATION; RIBAVIRIN; THERAPY;

D O I：

10.1007/s40121-020-00303-8

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The emergence of SARS-CoV-2/2019 novel coronavirus (COVID-19) has created a global pandemic with no approved treatments or vaccines. Many treatments have already been administered to COVID-19 patients but have not been systematically evaluated. We performed a systematic literature review to identify all treatments reported to be administered to COVID-19 patients and to assess time to clinically meaningful response for treatments with sufficient data. We searched PubMed, BioRxiv, MedRxiv, and ChinaXiv for articles reporting treatments for COVID-19 patients published between 1 December 2019 and 27 March 2020. Data were analyzed descriptively. Of the 2706 articles identified, 155 studies met the inclusion criteria, comprising 9152 patients. The cohort was 45.4% female and 98.3% hospitalized, and mean (SD) age was 44.4 years (SD 21.0). The most frequently administered drug classes were antivirals, antibiotics, and corticosteroids, and of the 115 reported drugs, the most frequently administered was combination lopinavir/ritonavir, which was associated with a time to clinically meaningful response (complete symptom resolution or hospital discharge) of 11.7 (1.09) days. There were insufficient data to compare across treatments. Many treatments have been administered to the first 9152 reported cases of COVID-19. These data serve as the basis for an open-source registry of all reported treatments given to COVID-19 patients at. Further work is needed to prioritize drugs for investigation in well-controlled clinical trials and treatment protocols.

引用

页码：435 / 449

页数：15

共 45 条

[21] Compassionate Use of Remdesivir for Patients with Severe Covid-19 [J].

Grein, J. ;

Ohmagari, N. ;

Shin, D. ;

Diaz, G. ;

Asperges, E. ;

Castagna, A. ;

Feldt, T. ;

Green, G. ;

Green, M. L. ;

Lescure, F-X ;

Nicastri, E. ;

Oda, R. ;

Yo, K. ;

Quiros-Roldan, E. ;

Studemeister, A. ;

Redinski, J. ;

Ahmed, S. ;

Bernett, J. ;

Chelliah, D. ;

Chen, D. ;

Chihara, S. ;

Cohen, S. H. ;

Cunningham, J. ;

Monforte, A. DArminio ;

Ismail, S. ;

Kato, H. ;

Lapadula, G. ;

L'Her, E. ;

Maeno, T. ;

Majumder, S. ;

Massari, M. ;

Mora-Rillo, M. ;

Mutoh, Y. ;

Nguyen, D. ;

Verweij, E. ;

Zoufaly, A. ;

Osinusi, A. O. ;

DeZure, A. ;

Zhao, Y. ;

Zhong, L. ;

Chokkalingam, A. ;

Elboudwarej, E. ;

Telep, L. ;

Timbs, L. ;

Henne, I ;

Sellers, S. ;

Cao, H. ;

Tan, S. K. ;

Winterbourne, L. ;

Desai, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (24) :2327-2336

[22]

Jaillon S, 2019, SEXUAL DIMORPHISM IN, P308

[23] Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? [J].

Karlberg, J ;

Chong, DSY ;

Lai, WYY .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 159 (03) :229-231

[24] Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome [J].

Kim, Uh Jin ;

Won, Eun-Jeong ;

Kee, Seung-Jung ;

Jung, Sook-In ;

Jang, Hee-Chang .

ANTIVIRAL THERAPY, 2016, 21 (05) :455-459

[25] Anti-SARS coronavirus agents: a patent review (2008-present) [J].

Kumar, Vathan ;

Jung, Young-Sik ;

Liang, Po-Huang .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2013, 23 (10) :1337-1348

[26] Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor [J].

Lan, Jun ;

Ge, Jiwan ;

Yu, Jinfang ;

Shan, Sisi ;

Zhou, Huan ;

Fan, Shilong ;

Zhang, Qi ;

Shi, Xuanling ;

Wang, Qisheng ;

Zhang, Linqi ;

Wang, Xinquan .

NATURE, 2020, 581 (7807) :215-+

[27]

Leong HN, 2006, ANN ACAD MED SINGAP, V35, P326

[28] Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome [J].

Lew, TWK ;

Kwek, TK ;

Tai, D ;

Earnest, A ;

Loo, S ;

Singh, K ;

Kwan, KM ;

Chan, Y ;

Yim, CF ;

Bek, SL ;

Kor, AC ;

Yap, WS ;

Chelliah, YR ;

Lai, YC ;

Goh, SK .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (03) :374-380

[29] Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome - A preliminary study [J].

Loutfy, MR ;

Blatt, LM ;

Siminovitch, KA ;

Ward, S ;

Wolff, B ;

Lho, H ;

Pham, DH ;

Deif, H ;

LaMere, EA ;

Chang, M ;

Kain, KC ;

Farcas, GA ;

Ferguson, P ;

Latchford, M ;

Levy, G ;

Dennis, JW ;

Lai, EKY ;

Fish, EN .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (24) :3222-3228

[30]

Marriott I, 2006, SEXUAL DIMORPHISM IN, P177

← 1 2 3 4 5 →